🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07565597
Active, not recruiting Phase 1

A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants.

NCT07565597 · tracked via the Priya Life Science China tracker
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase
Phase 1
Started
2026-05-12
Last updated
2026-06-08

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

Gecacitinib Hydrochloride Tablets

Gecacitinib Hydrochloride Tablets: Administered orally

Study summary

This study will compare the pharmacokinetics (PK) effect of two different formulations of Gecacitinib Hydrochloride Tablets in healthy Adult participants

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * 18≤ age ≤ 45, male or female; * Body weight: ≥50 kg for male, ≥45 kg for female; body mass index (BMI): 19.0-26.0 kg/m\^2 (inclusive); * Informed consent will be signed before the trial, and the content, process and possible adverse reactions of the study will be fully understood; * The volunteers should be able to communicate well with the researchers and understand and comply with the requirements of the study. Exclusion Criteria: * Participants who were enrolled in a clinical trial or used a study drug within 3 months before administration of the study drug. * Participants may not be able to complete the study for other reasons or have other reasons for not participating in the study as judged by the investigator.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Third Hospital of Changsha Changsha Hunan

More Suzhou Zelgen Biopharmaceuticals Co.,Ltd trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07565597 on ClinicalTrials.gov ↗ ← All trials in China